Allt inom Q1
Nanexa publishes interim report for January – March 2023
Positive pre-clinical data with NEX-22, NEX-20 phase I continues and good progress in partner projects
Nanexa publishes interim report for January – March 2022
Positive development in the product projects and in the patent portfolio
